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Emily K. Sims 
MICRORNA 21 TARGETS B CELL LYMPHOMA 2 (BCL2) MRNA TO INCREASE 
BETA CELL APOPTOSIS AND COULD SERVE AS A BIOMARKER OF 
DEVELOPING TYPE 1 DIABETES MELLITUS 
The role of beta cell miR-21 in Type 1 Diabetes (T1D) pathophysiology has been 
controversial. Here, we sought to define the context of beta cell miR-21 upregulation in 
T1D and the phenotype of beta cell miR-21 overexpression through target identification. 
Furthermore, we sought to identify whether circulating extracellular vesicle (EV) beta 
cell-derived miR-21 may reflect inflammatory stress within the islet during T1D 
development.. Results suggest that beta cell miR-21 is increased in in-vivo models of 
T1D and cytokine-treated cells/islets.  miR-21 overexpression decreased cell count and 
viability, and increased cleaved caspase-3 levels, suggesting increased cell death.  In 
silico prediction tools identified the anti-apoptotic mRNA B Cell Lymphoma 2 (BCL2) as 
a conserved miR-21 target. Consistent with this, miR-21 overexpression decreased BCL2 
transcript and protein expression, while miR-21 inhibition increased BCL2 protein levels 
and reduced cleaved caspase-3 levels following cytokine-treatment.  miR-21-mediated 
cell death was abrogated in 828/33 cells, which constitutively overexpress BCL-2. 
Luciferase assays suggested a direct interaction between miR-21 and the BCL2 
3’untranslated region. With miR-21 overexpression, PRP revealed a shift of BCL-2 
message toward monosome-associated fractions, indicating inhibition of BCL2 
translation. Finally, overexpression in dispersed human islets confirmed a reduction in 
BCL2 transcripts and increased cleaved caspase 3 production.  Analysis of EVs from 
human beta cells and islets exposed to cytokines revealed a 3-5-fold increase in miR-21.  
   v 
Nanoparticle tracking analysis showed no changes in EV quantity in response to 
cytokines, implicating specific changes within EV cargo as responsible for the miR-21 
increase.  Circulating EVs from diabetic non-obese diabetic (NOD) mice displayed 
progressive increases in miR-21 that preceded diabetes onset.  To validate relevance to 
human T1D, we assayed serum samples collected from 19 pediatric T1D subjects at the 
time of diagnosis and 16 healthy controls.  Consistent with our NOD data, EV miR-21 
was increased 5-fold in T1D samples.  In conclusion, in contrast to the pro-survival role 
reported in other systems, our results demonstrate that miR-21 increases beta cell death 
via BCL2 transcript degradation and inhibition of BCL2 translation. Furthermore, we 
propose that EV miR-21 may be a promising marker of developing T1D. 
 
Carmella Evans-Molina M.D., Ph.D., Chair 
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CHAPTER ONE: INTRODUCTION/BACKGROUND  
The Clinical Problem 
The global and domestic incidence of Type 1 Diabetes (T1D) is rising at a rate of 
nearly 3% per year, and contributes an annual cost of $14.4 billion to U.S. health 
expenditures (1-4).  Data from large clinical studies like the Diabetes Prevention Trial-1 
suggest that subtle perturbations in beta cell function can be measured up to 18 months 
prior to clinical presentation (5).  After clinical presentation, patients often display 
residual beta cell function that progressively declines over the course of the disease (6). 
Whereas immunomodulatory therapies have shown some efficacy in attenuating T1D 
progression when administered at the time of diagnosis, the long-term effectiveness of 
these drugs is limited (7-10). These failures are related, in part, to ongoing autoimmunity, 
but emerging data also suggest beta cells themselves may not be innocent bystanders in 
human T1D development. Rather, metabolic stress pathways intrinsic to the beta cell, 
which may be initially activated to provide mechanisms for increasing cell survival and 
insulin production, could theoretically hasten the progression to apoptosis or enhance 
beta cell responsiveness to immune infiltration and/or to immune-mediated destruction 
(11, 12). Beta cells from rodent models and individuals with T1D demonstrate increased 
stress markers compared to controls, and evidence exists to suggest these changes 
precede the development of T1D (13-16). These findings suggest that limited efficacy of 
immunotherapies in human T1D may also reflect inadequate treatment of T1D-related 
beta cell dysfunction (17). Along these lines, there exists an urgent need to delineate 
contributions of intrinsic beta cell dysfunction to T1D development, which may 
ultimately pave the way for novel beta cell targeted therapies to be used in combination 
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with immunomodulatory approaches. Additionally, limited successes of conventional 
therapies are likely also a consequence of irreparable damage to the functional beta cell 
pool that has accumulated by the time of clinical presentation. Thus, strategies to define 
biomarkers to identify and monitor abnormalities in beta cell health are also crucial goals 
for T1D research. Such strategies would allow for earlier identification of incipient T1D, 
prior to the development of hyperglycemia and widespread beta cell destruction, and 
permit earlier administration and improved outcomes of novel and traditional T1D 
therapies. 
Beta cell inflammation and microRNAs (miRNAs)  
 An improved understanding of intrinsic stress pathways activated during T1D 
development may pave the way for beta cell targeted therapies. One such pathway of 
interest is the NF-κB signaling pathway, which is induced within the islet in response to 
inflammatory cytokines, hyperglycemia, and oxidative stress (14, 18-20).  Interestingly, 
NF-κB signaling in the beta cell has been linked to both pro- and anti-apoptotic gene 
expression, suggesting complex and multifaceted regulation of this signaling pathway 
under inflammatory conditions (19, 21).   
 microRNAs (miRNAs) are short, noncoding RNAs that classically inhibit gene 
expression by increasing messenger RNA (mRNA) degradation or directly inhibiting 
mRNA translation (22). Multiple studies have identified miRNAs as key regulators of 
beta cell development, glucose-stimulated insulin secretion, and beta cell dysfunction 
(23-31). Global expression profiling performed in human and rodent islets subjected to 
pro-inflammatory cytokine stress and viral infection as models of T1D demonstrates 
marked changes in miRNA expression patterns (27, 28, 32).  These findings suggest that 
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beta cell miRNAs may also contribute to activation of intrinsic beta cell stress pathways 
that act to augment or even initiate beta cell dysfunction and death during the 
development of T1D  (11).  
 Tissue-derived miRNAs circulate and are stable in the blood, and differences 
within serum/plasma fractions have been described (33-35).   In particular, miRNAs are 
often enriched in EVs. These membrane bound nanoparticles, classified as exosomes, 
microvesicles, or apoptotic bodies, develop from exocytosis of multivesicular bodies 
(exosomes) or blebbing of the parent cell plasma membrane (microvesicles and apoptotic 
bodies) (36). EV molecular cargo, including RNAs, DNA, lipids, and protein, are 
determined by regulated processes and are altered by disease states (36-39). Specifically, 
beta cell EVs and their cargo have physiologic relevance to the T1D microenvironment 
(40-47). Islet EVs contain beta cell autoantigens and are able to increase antigen 
presentation and inflammatory cytokine production by antigen presenting cells, as well as 
stimulate endothelial cell angiogenesis (40-42). Importantly, cytokine treatment of beta 
cell lines or islets to mimic developing T1D induces physiologic changes in beta cell EV 
content that can impact recipient cells (40, 43-45). For example, treatment of beta cells 
with EVs from cytokine-treated parent beta cells can induce dose-dependent effects on 
recipient cell survival via transfer of EV microRNAs (43, 45). EVs from cytokine-treated 
islets also display enhanced immunostimulatory properties (40). 
miRNA 21 (miR-21) is a Nuclear Factor-!b (NF-!b) dependent miRNA shown to 
be induced during the evolution of T1D (46, 48, 49). This miRNA has been well 
characterized in other cell types, and has been classically been labeled an “oncomiR” in 
cancer cells, due to inhibition of tumor suppressor genes, leading to pro-survival effects 
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(50-52).  However, miR-21’s role in the beta cell has been less clear, with conflicting 
data regarding pro-survival versus pro-apoptotic effects (46, 48, 53).  Similarly, although 
elevations in circulating miR-21 have been reported in subjects with longstanding T1D, 
the specific etiology of these changes and differences during developing T1D have not 
been described (54, 55).   
As illustrated in Figure 1, we hypothesized that miR-21 expressed by the beta cell 
in response to inflammatory stress impacts beta cell survival during T1D development.  
Furthermore, we proposed that differences in EV serum miR-21 levels may identify the 
activation of intrinsic beta cell stress pathways in emerging T1D and allow for the earlier 
clinical identification of T1D onset. Using human islets and cell line models of T1D,  we 
sought to define the context of beta cell miR-21 upregulation and the phenotype of beta 
cell miR-21 overexpression by novel target identification.   Our findings demonstrate an 
interaction between beta cell miR-21 and the antiapoptotic mRNA B Cell Lymphoma 2 
(BCL2), resulting in dual effects on BCL2 transcript abundance as well as BCL2 
translation. In addition, we detected increased human islet EV miR-21 in response to 
cytokine-induced pro-inflammatory stress, and increased serum EV mir-21 in prediabetic 
NOD mice and children with recent onset T1D.  These findings suggest that EV miR-21 
may be a promising circulating biomarker of beta cell inflammation and developing T1D. 
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Figure 1. Proposed model of miR-21 production in response to cytokine stress in the 
microenvironment of T1D.  Inflammatory cytokines in the T1D microenvironment 
activate the NFĸB signalling pathway, increasing miR-21 transcription.  miR-21 binds to 
BCL2  transcripts resulting in transcript degradation and inhibiting translation of  the 
antiapoptotic molecule.  miR-21 is secreted extracellularly in extracellular vesicles. 
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CHAPTER TWO: METHODS AND RESULTS  
Animals, Islets, and Cell Culture 
 Eight-week old male C57BL6/J mice (Jackson Laboratories, Bar Harbor, Maine) 
were treated with normal saline or multiple low dose streptozotocin (MLD-STZ) 
administered intraperitoneally at a dose of 35 mg/kg/day for 5 days to induce diabetes. 
Blood glucose was measured via tail vein nick using an Alphatrack glucometer (Abbott 
Laboratories, Abbott Park, IL). Pancreatic islets were isolated by collagenase digestion 
one week after STZ initiation as previously described (56). Eight-week old female 
nonobese diabetic (NOD, Jackson Labs) mice were followed weekly with serum 
collections and blood glucose measurements for onset of diabetes (blood glucose 
>11.1mmol/l), when islets were isolated for analysis. Non-diabetic NOD mice were 
followed until 20 weeks of age to rule out diabetes development, then euthanized for islet 
isolation. Blood collection for serum isolation and glucose measurements were done via 
tail vein nick.  Blood glucose was measured using AlphaTRAK glucometer (Abbott 
Laboratories) following manufacturer’s instructions.  Serum samples were isolated using 
Microvette CB 300 system for capillary blood collection (Sarstedt).  Islets were also 
isolated from age matched CD1 or NOR/Ltj mice (Jackson Labs). Animals were 
maintained within the Indiana University Laboratory Animal Resource Center under 
pathogen-free conditions and protocols approved by the institutional animal care and use 
committee, in accordance with the Guide for the Care and Use of Laboratory Animals 
(57). 
Rat insulinoma (INS-1) (832/13) and (828/33) cells, Human EndoC-"H1 
(EndoC), or mouse insulinoma (MIN6) beta cells, or cadaveric human islets from 
	 7 
nondiabetic donors (obtained from the Integrated Islet Distribution Program, exempt 
from Institutional Review Board approval) were cultured as described (58, 59) and 
treated with a cytokine mix consisting of 5ng/ml IL-1beta, 100ng/ml IFN-γ, and 10ng/ml 
TNF-α for 6, 24, or 48 hours.  INS-1 cells were also treated with high glucose (25 
mmol/l) or tunicamycin (300nmol/l) for 24 hours.   
INS-1 (832/13) and (828/33) cells were seeded into a 12-well plate at a density of 
4x105 cells/well and treated for 48 hours with miR-21 5p (accession # MI0000569) 
mimic used at a concentration of 45 pmol (Qiagen, Germany), or 100 pmol locked 
nucleic acid (LNA) inhibitor (Exiqon, Denmark), or negative controls (Qiagen, Exiqon) 
that had been complexed with 3 µl Lipofectamine 3000 and 100 µl Opti-Mem (Thermo 
Fisher, Grand Island, NY). 
For human islet dispersion and transfection, after 4 hours of routine incubation at 
37° C, islets were suspended in 4 ml of Accutase solution (Millipore, Billerica, MA) with 
100 units of DNase I (Millipore) in a thermal mixer at 37 degrees, 1000 rpm for 10 
minutes, followed by addition of 10ml of culture medium. Dispersed cells were collected 
by centrifugation at 200g for 3 minutes, then resuspended in culture medium and seeded 
into 12-well tissue culture plates (Falcon, Tewksbury, MA).  Dispersed cells from 200 
islets were transfected with 23 pmol of either negative control miRNA or miR-21 mimic 
using Lipofectamine 3000 reagent as described above. Cleaved caspase 3 ELISA 
(ThermoFisher) was performed on transfected human islets per the manufacturer’s 
protocol.  
Luciferase assays were performed using a Gaussia Luciferase/secreted alkaline 
phosphatase dual reporter system (Genecopoeia, Rockville, MD). Plasmids containing the 
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cloned wildtype human BCL2 3’ untranslated region (UTR) or a mutated 3’UTR 
(positions 710-716 or 720-726) downstream of a secreted gaussia luciferase reporter, 
driven by an SV40 promoter and a secreted alkaline phosphatase reporter driven by a 
CMV promoter were generated by Genecopoeia. INS-1 cells were seeded in a 12-well 
plate and then treated with 1µg of plasmid DNA complexed with 3 µl of lipofectamine 
3000 (in 100 µl Optimem) for 24 hours.  Cells were then trypsinized and reseeded, 
followed by transfection with a miR-21 mimic or negative control, as above, for 24 
hours. A dual reporter luciferase assay kit (Genecopoeia) was used as per manufacturer’s 
instructions to quantify luciferase activity in 10 µl of media.  Results were normalized to 
secreted alkaline phosphatase activity measured using a SpectraMax M5 multiwell plate 
reader (Molecular Devices, Sunnyvale, CA). 
Cell counting was performed using 20 µl of trypsinized and resuspended INS-1 
cells on a Cellometer (Nexcelom Bioscience, Lawrence, MA). Live/dead staining was 
performed with Acridium Orange/ Propidium Iodide Dye (AOPI) (Nexcelom Bioscience) 
mixed 1:1 with suspended cells after trypsinization. Fluorescence detection of reactive 
oxygen species generation in INS-1 cells was performed using CellROX Deep Red 
Reagent (ThermoFisher) per manufacturer’s instructions.  Cells were imaged on a LSM 
700 fluorescent confocal laser scanning microscope (Zeiss, Germany), and fluorescence 
intensity was assessed as mean signal per well using ZEN 2011 image processing 
software (Zeiss). 
RNA isolation and reverse transcription was performed using miRNeasy and 
miScript II RT kits according to the manufacturer’s instructions (Qiagen). Quantitative 
reverse transcription polymerase chain reaction (qRT-PCR) was performed using the 
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miScript SYBR Green PCR Kit (Qiagen) and a Mastercycler ep realplex instrument 
(Eppendorf, Hauppage, NY). Relative RNA levels were established against the invariant 
small nuclear RNA RNU6-1 for miRNAs and beta-actin for mRNA species, using the 
comparative CT method (60). Relative miRNA levels from EV isolates were established 
against C. elegans miR-39 mimic spike-in control (Qiagen).  
Immunoblot analysis was performed as previously described (61). Briefly, equal 
concentrations of total protein were separated by SDS-PAGE and transferred to a 
polyvinylidene fluoride membrane, and incubated at 4 degrees overnight with primary 
antibodies. 1:750 dilutions of rabbit anti-B Cell Lymphoma 2 (BCL2), rabbit anti-
Programmed Cell Death 4 (PDCD4), and rabbit anti-cleaved caspase-3 (Cell Signaling, 
Danvers, MA) and a 1:10,000 dilution of mouse anti-actin antibody (Millipore) were 
used. Bound primary antibodies were detected with donkey anti-mouse or donkey anti-
rabbit antibodies (both at 1:10,000 dilutions, LICOR Biosciences, Lincoln, NE). 
Immunoreactivity was visualized using fluorometric scanning on an Odyssey imaging 
system and quantified by LI-COR software. 
Polyribosomal profiling (PRP) experiments were performed as previously 
described (62).  Briefly, INS-1 cell lysates were centrifuged through a 10-50% sucrose 
gradient for 2 hours at 40,000 rpm, and fractionated using a BioComp piston gradient 
fractionator. RNA absorbance at 254 nm was recorded using an inline UV monitor, and 
fractions were collected. Total RNA was reverse transcribed and qRT-PCR was 
performed using SYBR Green methodology as above. 
Glucose stimulated insulin secretion (GSIS) was assayed as described (63). 
Supernatants were collected and assayed using a radioimmunometric assay for insulin 
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(Millipore). Values were normalized to total insulin content of the islet fraction. 
Polyribosomal profiling (PRP) experiments were performed on INS-1 cell lysates as 
previously described (62). Total RNA was reverse transcribed and qRT-PCR was 
performed using SYBR Green methodology as above. 
EV Isolation 
Total EVs were isolated from culture media using ExoQuick TC reagent (System 
Biosciences) and circulating EVs were isolated from 50 uL of serum using ExoQuick 
reagent (System Biosciences) following manufacturer’s guidelines.  Sequential 
centrifugation was utilized to separate EVs by size.  The samples were centrifuged at 
800g for 15 minutes to remove dead cells and cellular debris, after which the supernatant 
was centrifuged at 2,000g to pellet large EVs/apoptotic bodies. 10,000g centrifugation of 
the supernatant from the previous step was utilized to collect microvesicles, and finally 
supernatant from the previous step was centrifuged at 100,000g to pellet the exosomes 
(64).  The remaining supernatant was also retained for analysis.  
Isolation and relative purity of the EVs were confirmed by nanoparticle tracking 
analysis (NTA), transmission electron microscopy (TEM), and western blot (WB).  
Samples enriched for EVs of interest were analyzed for concentration and size 
distribution with dynamic light scattering using a ZetaView instrument for NTA 
(ParticleMetrix).  Prior to measurement, the system settings were calibrated using 100nm 
polystyrene particles.  NTA measurement was recorded and analyzed at 11 positions per 
sample with ZetaView Analyze software (ParticleMetrix).  EV-enriched sample 
preparations were fixed in EM-grade fixative containing 2% glutaraldehyde and 2% 
paraformaldehyde in 0.1M buffered phosphate for at least 30 mins at 4°C.  After fixation, 
samples were placed on 200 mesh silicon monoxide formvar coated grids and stained 
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with NanoVan (Nanoprobes).  Images were taken on an FEI Technai G2 Spirit TEM 
microscope.  Fixed samples were processed and imaged by the University of Nebraska 
Medical Center EM Core. 
Human Subjects. 
 This study was approved by the Indiana University Institutional Review Board. 
Informed consent was obtained from parents with assent from children. Random serum 
samples were obtained from pediatric subjects diagnosed with T1D by a pediatric 
endocrinologist within 3 days of T1D diagnosis. Samples were collected in serum 
separator tubes and serum was isolated by centrifugation and stored at -80° C. Exclusion 
criteria included diabetic ketoacidosis requiring an intensive care unit stay, diabetes other 
than T1D, history of prior chronic illness known to affect glucose metabolism, or use of 
medications known to affect glucose metabolism. Control serum from healthy pediatric 
subjects was obtained from a biorepository at Indiana University School of Medicine.   
 
Statistics 
 Statistical analyses were performed using GraphPad Prism Version 6.00 
(GraphPad Software, La Jolla, California).  Student’s t-tests were used for comparison 
between treatment and control groups.  One-way analysis of variance (ANOVA) with 
Tukey’s post-test for multiple comparisons was utilized when comparing >2 groups.   For 
human data, Mann-Whitney U test, or Kruskal-Wallis analysis of variance with Dunn’s 
posttest for analysis of more than 2 groups were used for nonparametric distributions. For 
all analyses, a p value of ≤ 0.05 was considered significant.   
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Results 
Beta cell miR-21 production is induced in models of inflammation and T1D. 
In order to determine whether inflammation present during the development of 
T1D was responsible for induction of beta cell miR-21, several models of T1D were 
utilized.  Islets were isolated from two in vivo mouse models of T1D: mice treated with 
MLD-STZ (obtained one week after treatment initiation), and NOD mice (at the time of 
diabetes onset).  Mice treated with MLD-STZ had increased islet miR-21 expression 
relative to saline-injected controls (Figure 2A), while islets from diabetic NOD mice 
demonstrated an even more pronounced increase in miR-21 expression compared to CD1 
controls (Figure 2B). Next, INS-1 832/13 cells were treated with a cytokine mix for 6, 
24, and 48 hours, and significantly increased miR-21 expression was observed at all 
timepoints (Figure 2C-E). To define whether this effect on miR-21 could be related to 
other components of the diabetic milieu, INS-1 cells were treated with 25mM glucose, to 
induce glucotoxicity and oxidative stress, or 300 nm tunicamycin for 24 hours, to induce 
endoplasmic reticulum (ER) stress (Figure 2F-G). Neither condition increased miR-21 
expression, suggesting that miR-21 was upregulated specifically in response to pro-
inflammatory signaling and not in response to hyperglycemia or ER stress. 
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Figure 2.  Beta cell miR-21 production is induced in models of inflammation and 
T1D.  miR-21 expression was analyzed in: A. islets from mice treated with multiple low 
doses of STZ (MLD-STZ) or saline controls (n=5), or B. diabetic NOD mice (n=7) 
compared to CD1 controls (n=5), C-E. INS-1 beta cells were treated with an 
inflammatory cytokine mix of 5ng/mL IL-1beta, 100ng/mL IFN-γ, and 10ng/mL TNF-α 
for 6, 24, and 48 hours (n=5-9), F. INS-1 cells were treated with 24 hours of high glucose 
(25 mM) or G. tunicamycin (300nM) for 24 hours (n=5-6). *p≤0.05; **p≤0.01, and ***p 
≤0.001 
0
1
2
3
m
iR
-2
1
R
el
at
iv
e 
Ex
pr
es
si
on
INS-1: 24-Hour
High Glucose
Control 24-Hours
High Glucose
0
1
2
3
m
iR
-2
1
R
el
at
iv
e 
Ex
pr
es
si
on
INS-1: 24-Hours
Tunicamycin
Control 24-Hours
Tunicamycin
F. G.
0
1
2
3
m
iR
-2
1
R
el
at
iv
e 
Ex
pr
es
si
on
INS-1: 6-Hour
Cytokine Treatment
**
Control 6-Hours
Cytokines
0
1
2
3
m
iR
-2
1
 R
el
at
iv
e 
Ex
pr
es
si
on
INS-1: 24-Hour
Cytokine Treatment
***
Control 24-Hours
Cytokines
0
1
2
3
m
iR
-2
1
R
el
at
iv
e 
Ex
pr
es
si
on
INS-1: 48-Hour
Cytokine Treatment
*
Control 48-Hours
Cytokines
C. D. E.
0.0
0.5
1.0
1.5
2.0
m
iR
-2
1
R
el
at
iv
e 
Ex
pr
es
si
on
Control MLD-STZ
**
0
2
4
6
8
m
iR
-2
1
 R
el
at
iv
e 
Ex
pr
es
si
on
CD1
Controls
NOD
Diabetic
***
A. B.
	 14 
 
Beta cell effects of miR-21 overexpression 
To define the phenotypic effects of increased miR-21 expression, INS-1 832/13 
beta cells were transfected with an miR-21 mimic. After 48 hours, INS-1 cells with miR-
21 overexpression were significantly less confluent than cells transfected with a negative 
control (Figure 3A-B), prompting live/dead staining with AOPI (Figure 3A,C). AOPI 
staining revealed a significant increase in the percentage of dead INS-1 cells in response 
to miR-21 overexpression.  To ascertain whether activation of intrinsic death pathways 
was involved, immunoblot for cleaved capase-3 was performed (Figure 3D). A 
significant increase in cleaved caspase-3 protein levels confirmed a role for apoptosis in 
this phenotype. To understand the effect of miR-21 upregulation on beta cell function, 
GSIS was performed in INS-1 cells transfected with a miR-21 mimic.  In contrast to cells 
transfected with the negative control miRNA, INS-1 cells overexpressing miR-21 showed 
a blunted insulin secretory response to stimulation with high glucose (Figure 3E).   
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Figure 3.  miR-21 overexpression increases beta cell apoptosis and decreases 
glucose-stimulated insulin secretion.  INS-1 cells were transfected with a miR-21 
mimic for 48 hours to increase miR-21 activity.  A. Cells were stained with AOPI to 
assess viability, with green staining (AO) representing all cells and red staining (PI) 
representing compromised membranes.  B. Total cells and C. Percentage dead cells were 
analyzed using a cell counter. D. Immunoblot for cleaved caspase-3 was performed to 
assay contribution of apoptosis to the increased cell death observed with miR-21 
overexpression. E. After transfection with a miR-21 mimic, glucose stimulated insulin 
secretion of cells was assayed in response to low (2.5mM) and high (15 mM) glucose 
concentrations, and normalized to total insulin content of the cell lysate.  (n=6-9 for all 
experiments); *p≤0.05; **p≤0.01, ***p ≤0.001, and ****p ≤0.0001 
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miR-21 reduces BCL2 levels via directly targeting the BCL2 3’UTR, resulting in reduced 
mRNA levels and reduced translation of BCL2 transcripts.   
 Because the pro-apoptotic mRNA of the gene encoding Programmed Cell Death 4 
(PDCD4) has previously been confirmed as a target of beta cell miR-21, immunoblot for 
PDCD4 was performed.  Our results confirmed reduced PDCD4 protein levels, consistent 
with effective miR-21 overexpression (Figure 4A) (53).   However, our observation that 
miR-21 overexpression increased beta cell death was at odds with a predicted pro-
survival effect of reduced PDCD4.  Based on this, we turned to in silico prediction tools 
to identify other potential miR-21 targets to explain the pro-apoptotic phenotype of beta 
cell miR-21 overexpression (65, 66).  We found that the 3’UTR of the mRNA encoding 
the anti-apoptotic protein B Cell Lymphoma 2 (BCL2) was a predicted target for miR-21, 
with a predicted binding site that was well conserved among vertebrate species (66, 67).  
Figure 4B depicts predicted sites of interaction between the human BCL2 3’UTR and 
miR-21.  
 Supporting this prediction, BCL2 protein levels were reduced in parallel with 
increased miR-21 levels after 48 hours of cytokine treatment (Figure 4C). To verify this 
relationship, qRT-PCR was performed to assess relative BCL2 transcript quantity on INS-
1 832/13 cells transfected with a miR-21 mimic (Figure 4D).  This analysis revealed 
decreased transcript levels, consistent with mRNA degradation.  In contrast, no 
significant change in the abundance of transcripts of other BCL2 family members that 
would be expected to impact apoptosis were detected (Figure 4E).  To determine 
whether a direct interaction occurred between miR-21 and the BCL2 3’UTR, INS-1 cells 
were transfected with plasmids containing a luciferase reporter driven by the wild-type 
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BCL2 3’UTR, or BCL2 3’UTRs that had been mutated at 2 different sites included in the 
predicted miR-21 binding region, position 710-716 or position 720-726 (Figure 4F).  
Cells were then transfected with either the miR-21 mimic or a negative control.  
Consistent with a direct interaction of miR-21 and the BCL2 3’UTR, miR-21 
overexpression reduced luciferase activity of INS-1 cells expressing the wild-type BCL2 
3’UTR plasmid.  However, no effect of miR-21 overexpression was present in INS-1 
cells transfected with mutated 3’UTR plasmids. 
 To confirm a miR-21 mediated effect on protein levels, immunoblots for BCL2 
protein were performed on INS-1 cells after miR-21 mimic transfection.  This analysis 
demonstrated reduced levels of BCL2 protein with miR-21 overexpression (Figure 4G). 
To understand whether miR-21 mediated reductions in BCL2 protein occurred 
exclusively through mRNA degradation as shown in Figure 3D versus direct inhibition of 
translation, polyribosomal profiling experiments were performed to ascertain the 
translation status of BCL2 mRNA.  Although no global changes in mRNA translation 
were seen (Figure 4H), INS-1 cells overexpressing miR-21 revealed a shift of BCL2 
transcripts toward monosome-associated fractions, and away from the polysome-
associated fractions, indicating a reduction in active BCL2 translation (Figure 4I).  These 
results suggest that both mRNA degradation, as well as translational inhibition contribute 
to miR-21-mediated reductions in BCL2 protein levels. 
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Figure 4.  miR-21 reduces BCL2 levels via directly targeting the BCL2 3’UTR, 
resulting in reduced mRNA levels and reduced translation of BCL2 transcripts.  A.  
After transfection of miR-21 mimic, overexpression was verified by performing 
immunoblot for the known beta cell miR-21 target, PDCD4 (n=4).  B.  Predicted binding 
sites of miR-21 within BCL2 3’UTR. C. BCL2 protein levels are reduced by treatment 
with inflammatory cytokines (n=6).  D.  BCL2 mRNA levels after mimic transfection 
(n=8). E.  Expression of other BCL2 Family mRNAs after mimic transfection.  F. 
Luciferase assay was performed on cells expressing wild type BCL2 3’UTR or BCL2 3’ 
UTR mutated at position 710-716 or 720-726, then transfected with a miR-21 mimic 
(n=4). G.  Immunoblot after mimic transfection revealed a reduction in BCL2 protein 
levels (n=8). H-I: Polyribosomal profiling was performed to ascertain effects of miR-21 
overexpression on BCL2 mRNA translation (n=3).  H. A representative global profile is 
pictured. I. Aggregated data from 3 experiments revealing a left shift of BCL2 mRNA 
away from polysome-associated fractions, with a significantly decreased percentage of 
transcripts in fraction 8, indicating a reduction in active translation. *p≤0.05; **p≤0.01, 
***p ≤0.001, and ****p ≤0.0001 
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Validation of effects of miR-21 overexpression in human islets 
 To validate relevancy of our findings in a human model, human islets were treated 
with a mix of pro-inflammatory cytokines for 24 and 48 hours.  Similar to results 
obtained in rodent beta cell lines and islets, we observed a significant increase in miR-21 
expression at the 48-hour time point (Figure 5A -B).  To confirm a direct role of miR-21 
on BCL2 and apoptosis in human islets, we transfected miR-21 mimics into dispersed 
islets.  Consistent with our findings above, we observed that miR-21 overexpression led 
to an increase in cleaved caspase 3 (measured using ELISA) and a reduction in BCL2 
expression (Figure 5C -D). 
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Figure 5.  Human islet miR-21 is increased by inflammatory cytokine treatment, 
and increases apoptosis in association with reduced BCL2 expression.  A-B. miR-21 
expression was quantified after human islets were treated with an inflammatory cytokine 
mix of 5ng/mL IL-1beta, 100ng/mL IFN-γ, and 10ng/mL TNF-α for 24 and 48 hours.  C. 
Cleaved caspase 3 expression was quantified using ELISA in dispersed human islets after 
miR-21 mimic transfection. 48-hour treatment with cytokine mix is also included as a 
positive control. (n=3) D. BCL2 transcripts were quantified after mimic transfection. 
(n=4) *p≤0.05; 
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Effects of beta cell miR-21 inhibition 
 To define effects of miR-21 inhibition, INS-1 cells were transfected with a miR-
21 inhibitor for 48 hours (Figure 6A-B).  At baseline, a trend towards increased BCL2 
was present (Figure 6A), while PDCD4 levels were unchanged (Figure 6B). To 
determine whether miR-21 inhibition had a protective effect against proinflammatory 
cytokines, INS-1 cells were treated for 16 hours with a proinflammatory cytokine mix.  
Interestingly, in combination with cytokine treatment, miR-21 inhibition reduced cleaved 
caspase-3 levels compared to negative controls (Figure 6C).  Here, there was a trend 
towards increased BCL2 levels in cells pretreated with the miR-21 inhibitor (Figure 6D).  
Again, no differences were present in PDCD4 levels (Figure 6E). 
 In order to ascertain the contribution of BCL2 inhibition on miR-21’s pro-death 
effects, we transfected INS-1 828/33 cells, which constitutively overexpress BCL2, with 
a miR-21 mimic (59).  BCL-2 levels were decreased by the miR-21 mimic.  However, 
BCL-2 expression remained higher than levels observed in the wild-type INS-1 cells 
(Figure 6F).  Consistent with this, the percentage of dead cells (assessed by AOPI 
staining, quantified in Figure 6G) was significantly lower in BCL-2 overexpressing INS-
1 cells compared to wild-type INS-1 cells transfected with the mimic. 
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Figure 6  miR-21 inhibition reduces cytokine-induced cleaved caspase-3 production, 
while BCL2 overexpression reduces miR-21 mediated apoptosis.  A-B. miR-21 LNA 
inhibitor was transfected in INS-1 832/13 (wild-type) beta cells for 48 hours to inhibit 
miR-21 activity.  Immunoblots for: A. BCL2 and B. PDCD4 were performed.   C-E. 
After miR-21 inhibitor treatment, INS-1 832/13 cells were treated with 16 hours of 
cytokine mix and immunoblots were performed for C. Cleaved Caspase-3, D. BCL2, and 
E. PDCD4.  F-G. INS-1 828/33 cells, which constitutively overexpress BCL2, were 
transfected with a miR-21 mimic for 48 hours.  F. Immunoblot for BCL2.  G. Percentage 
dead cells. (n=3-5); *p≤0.05; **p≤0.01, and ***p ≤0.001 
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Beta Cell EV miR-21 Release is Increased After Exposure to Inflammatory Cytokines 
To determine whether developing T1D increases beta cell EV miR-21, we also 
quantified miR-21 in EVs from INS-1 cells and human islets after treatment with 24 
hours of the inflammatory cytokine mix (Figure 7A,C). Here, cytokine exposure induced 
a 3-6 fold increase in total EV miR-21.  Interestingly, the levels of increase in EV miR-21 
from the EndoC human beta cells and from human islets were of higher magnitude than 
the increases in miR-21 expression, suggesting specific trafficking of miR-21 to the EVs.  
To understand whether increased levels of EV miR-21 may be related to possible 
increased release of EVs under inflammatory conditions, we performed nanoparticle 
tracking analysis (NTA) to determine EV quantity and size distribution.  No significant 
differences in either the size distribution or particle concentration were detected in INS-1 
cells or in human islets after 24 hours of cytokine treatment (Figure 7B-C). These data 
suggest that the cytokine-induced increase in beta cell EV miR-21 is due to specific 
increases within the vesicle cargo, and not an effect of an increased net release of EVs.    
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Figure 7. Inflammatory cytokine exposure increases beta cell EV miR-21.  INS-1 
cells and human islets  were treated with cytokine mix of IL-1beta, INFγ, and TNFα for 
24h. A,C. miR-21 levels were assessed by qRT-PCR in EVs from INS-1 cells and from 
human islets. (n=3-6). NTA was performed to profile EV particle concentration and size 
distribution from cytokine treated B. INS-1 cells, and D. human islets. (n=3 each) Results 
displayed as mean ±SD; *p ≤ 0.05, **p ≤ 0.01 
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Cytokine-induced increases in beta cell EV mir-21 are predominantly due to beta cell 
exosome miR-21 
We next endeavored to determine whether cytokine-induced increases in beta cell 
EV miR-21 may be specific to a particular EV subtype.  To this end, we utilized 
sequential ultracentrifugation to separate EVs by size, allowing for isolation of larger 
EVs (apoptotic bodies), medium sized EVs (microvesicles), and smaller vesicles 
(exosomes) (68, 69).  Western blot, and TEM were performed to validate isolations 
(Figure 8C-D). q-RTPCR of each fraction revealed that in INS-1 beta cells and in human 
islets, miR-21 was consistently increased in the apoptotic bodies and exosomes (Figure 
8A-B).  NTA analysis of centrifugation fractions revealed much higher number of 
exosomes than either microvesicles or the apoptotic bodies (Figure 8D-E).  Interestingly, 
the apoptotic bodies were present at very low concentration, despite being the earliest 
recovered fractions collected by the sequential centrifugation.  This finding suggests that 
apoptotic bodies, and possibly other large EVs, are responsible for only a minor fraction 
of the total observed increase in beta cell EV miR-21, with the exosomes being the 
primary type of vesicle carrying increased levels of miR-21. 
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Figure 8.  Increased EV miR-21 is specific to exosomes.  A-B. Media from cytokine-
treated INS-1 cells (n=3) and human islets (n=5) was separated by sequential 
centrifugation into large EV (apoptotic bodies), medium EV (microvesicle), and small 
EV (exosome) fractions. C. TEM and D. immunoblot of EndoC cell derived EVs were 
used to validate EV isolation by serial ultracentrifugation; E-G. NTA analysis was 
performed on each EV fraction.  TEM images display representative data from three 
independent experiments. Results displayed as mean ±SD; *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 
0.001, by 2-tailed t test.  
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Progressive elevations in circulating EV miR-21 precede the onset of diabetes in NOD 
Mice 
Based on increased beta cell EV mir-21 release in response to cytokine exposure 
ex vivo, we predicted that circulating EV miR-21 would also be increased during in vivo 
development of T1D. To test this prediction, we utilized the NOD mouse model of T1D.  
First, we tested islets from female diabetic NOD mice at the time of diabetes onset, as 
compared to NOR controls (Figure 9A).  We found a 2.5-fold increased expression of 
miR-21 in the islets of diabetic animals.  We then isolated EVs from terminal serum of 
diabetic mice, and detected a ~10 fold increase in the levels of miR-21 compared to NOR 
controls (Figure 9B). Next, to assess changes in circulating EV miR-21 during T1D 
development, we collected weekly serial serum samples from diabetic NOD mice starting 
at 8 weeks of age until the time of T1D onset (Figure 9C).  Here, we observed an age-
dependent increase in miR-21 in the circulating EVs of prediabetic NOD mice starting at 
12 weeks of age (Figure 9D).  To establish relationships to the development of T1D we 
normalized these values to those of age-matched NOR controls and plotted the data based 
on relative time to T1D onset (Figure 9E).  NTA of these circulating EVs revealed no 
significant variations in the EV concentration relative to age or prior to the onset of T1D 
(Figure 9F-G).  These data confirm that progressive increases in serum EV miR-21 
predate hyperglycemia during developing diabetes in this mouse model of T1D. 
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Figure 9. Elevations in circulating EV miR-21 precede onset of T1D in NOD mice.  
qRT-PCR was performed to quantify relative levels of EV miR-21 in the A. islets  and 
the B. terminal serum of diabetic NOD mice compared to NOR controls. C. Longitudinal 
weekly serum collections and blood glucose assessments of NOD (n=7-9) and control 
NOR (n=5) mice were performed, starting at 8 weeks of age and until either development 
of diabetes, or until 20 weeks of age. D: qRT-PCR was performed to quantify serum EV 
miR-21 in NOD mice relative to controls by age (n=3-9/group). E: NOD serum EV miR-
21 relative to age-matched NOR controls was also analyzed with relationship to diabetes 
onset (defined as first glucose >200 mg/dL).  NTA of serum EVs in NOD mice showed 
no significant changes with relation to age (F) or diabetes onset (G) (n=6). Results 
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displayed as mean ± SD; *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001 by 2-tailed Student’s t test, 
1-way ANOVA with Holm-Sidak’s multiple comparisons test, or 2-way ANOVA with 
Sidak’s multiple comparisons test. RQ=relative quantity.
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miR-21 is Increased in the Circulating EVs from New-Onset T1D Patients 
 
To establish relevance to human disease, we analyzed clinical serum samples 
from 19 pediatric subjects with new onset T1D and 16 healthy pediatric control subjects. 
Demographic characteristics are presented in Table 1; no significant differences in age, 
gender, or BMI percentile for age were present between groups.  We quantified total 
serum miR-21, total serum EVs and the miR-21 from circulating EVs.  In contrast to 
reports from subjects with longstanding T1D, total serum miR-21 was decreased in recent 
onset T1D patients compared to controls (Figure 10A).  However, consistent with our in 
vitro and NOD mouse findings, levels of serum EV miR-21 in were 5-fold increased in 
samples from T1D subjects (Figure 10B).  
We also performed NTA on serum samples to assess differences in the overall 
numbers and size distribution of circulating EVs that revealed a reduction total 
circulating EVs in T1D samples, specifically in smaller EVs (Figure 10C). We measured 
correlations between serum EV miR-21 and age, BMI Z-score, and HbA1c (for T1D 
subjects only).  In control subjects, younger age correlated with higher EV mir-21 levels 
(rs=-0.506, p=0.474).  However, this relationship was not present in T1D subjects. We 
did not detect any correlations between BMI percentile or HbA1c and EV miR-21 levels, 
but because our samples were collected at the time of T1D diagnoses, all subjects had 
uncontrolled T1D.  In addition, no differences were detected based on separation by 
gender.  
We also asked whether our observed differences in serum and EV miRNAs would 
apply to a different miRNA biomarker of diabetes.  For this analysis, we chose to 
measure miR-375, which has been proposed as a circulating biomarker of beta cell death 
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(Figure 10D-E) (70, 71). By contrast to miR-21, in participants with type 1 diabetes, 
miR-375 was similarly increased in both serum and in serum EVs.  We next examined 
associations between the relative levels of serum EV miR-21 and miR-375 among 
participants with diabetes (Figure 10F). Although there was overlap in some individuals, 
the levels of the two microRNAs were not correlated overall, with examples of 
individuals with predominant elevations in either serum EV miR-21 or serum EV miR-
375.  
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Table 1. Demographic characteristics of human subject groups.  
Variable Healthy Control 
(n= 16) 
T1D (n=19) P value 
Age (years) 10.5 (9, 12)  10.5 (8,12) 0.8579 
Male sex (%) 62.5 62.5 1.00 
BMI percentile 84 (72.5, 89.5) 52.5 (32.5, 87.5) 0.1343 
HbA1C 
(%/mmol/mol) 
n/a 11.3 (10.25,12.33) / 
 100 (89,111) 
n/a 
Results are displayed as median (Interquartile range).  T1D- Type 1 diabetes, BMI- body 
mass index, HbA1c-Hemoglobin A1c 
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Figure 10. Circulating EV miR-21 is elevated in persons with new-onset T1D. Serum 
samples from healthy pediatric controls (HC) and new-onset pediatric T1D subjects 
(T1D) were assessed for relative levels of circulating miR-21 in A. whole serum and in 
B. circulating EVs  by qRT-PCR (n=16-19/group).  C. NTA was performed to quantify 
serum EV concentration and size distribution. D. Relative levels of total serum miR-375-
5p and E. circulating EV miR-375-5p were also quantified.  F. Relationship between 
serum EV miR-21-5p and EV miR-375-5p in samples from individuals with type 1 
diabetes. Results shown as median ± IQR except Figure 10C (mean ± standard 
deviation);  *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001.  
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CHAPTER THREE: CONCLUSIONS  
Previous studies have demonstrated increased beta cell miR-21 expression in 
response to cytokines and inflammation, specifically via activation of NFκB signaling 
(46, 49, 53).  Consistent with other cell types, beta cell miR-21 has been confirmed to 
target the tumor suppressor PDCD4 (49, 53).  Knockout of islet PDCD4 protected against 
beta cell death and diabetes development in NOD mice, and after treatment with high 
dose STZ, suggesting that miR-21 mediated inhibition of PDCD4 could potentially have 
a pro-survival effect (53). However, others have shown that miR-21 overexpression via 
transfection demonstrated no improvement in beta cell survival (46). More recent work 
reported increased beta cell apoptosis after stable lentiviral miR-21 overexpression.  
However, the authors did not observe concurrent reductions in PDCD4 with miR-21 
overexpression, or identify a mechanism explaining potential pro-apoptotic effects of 
miR-21 (48), leaving a number of unresolved controversies regarding the effect of miR-
21 on beta cell survival and function.  
Consistent with other studies, we found that beta cell miR-21 was induced by 
multiple in vitro and in vivo models of inflammation and T1D, including cytokine 
treatment of human islets, islets from mice treated with MLD-STZ, and NOD mouse 
islets. Moreover, we ruled out contributions from ER stress or hyperglycemia associated 
with diabetes development. The elevation of miR-21 in non-diabetic NOD islets is an 
interesting finding, and consistent with inflammatory induction of miR-21 expression, as 
NOD-Severe Combined Immunodeficiency (NOD-SCID) mice exhibit islet macrophage 
and dendritic cell infiltration, increased TNF-α signaling, and intrinsic islet dysfunction, 
despite the absence of hyperglycemia (14, 72).  Of note, and consistent with islet miR-21 
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expression, we were unable to detect differences in islet BCL2 mRNA between diabetic 
and nondiabetic NOD mice (data not shown). 
 We endeavored to first clarify the effects of miR-21 on beta cell survival and 
secondly to identify a beta cell miR-21 target to explain these effects. In INS-1 beta cells, 
our results revealed that miR-21 overexpression, induced using a miR-21 mimic, led to a 
clear increase in cell death, despite reductions in PDCD4 protein levels. Correspondingly, 
inhibition of miR-21 was able to reduce cleaved caspase-3 expression after cytokine 
treatment.  Differences in our data and previous work may have several explanations, but 
are mostly likely due to differences in method, dose, and effectiveness of miR-21 
manipulation in target cells. However, we verified that our system resulted in effective 
miR-21 overexpression by ensuring significant suppression of PDCD4, a verified beta 
cell miR-21 target.  Furthermore, identification of a target that explains the pro-apototic 
phenotype lends credibility to our system and findings. 
Based on in silico prediction tools, we identified the BCL2 3’UTR as a highly-
conserved miR-21 binding site. BCL2, a member of the antiapoptotic BCL2-like-protein 
subgroup of the BCL2 protein family, is involved in regulation of mitochondrial outer 
membrane permeabilization and apoptosis (73).  When bound to BH3-only “activator” 
proteins, BCL2-like proteins are able to render activator proteins latent.  However, when 
the interaction between BCL2-like proteins and activator proteins is disrupted, activator 
proteins are released in to the cytoplasm, where they induce a conformational change and 
activation of pro-apoptotic Bax-like proteins.  This ultimately leads to pore formation in 
the outer mitochondrial membrane and release of pro-apoptotic proteins into the cytosol 
(73, 74).  Because of BCL2’s pro-survival properties, miR-21 mediated reductions in 
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BCL2 mRNA stability and suppression of BCL2 translation could explain the pro-
apoptotic phenotype we observed in beta cells (75, 76). 
 Although BCL2’s 3’UTR has a predicted miR-21 binding site, reduced BCL2 
levels have not been typically identified as an effect of miR-21.  To the contrary, in other 
cell types, miR-21 overexpression has been associated with increased BCL2 protein 
levels, (77-79). Treatment of breast cancer cells with estrogen receptor agonists was 
associated with reductions of miR-21 expression and increased BCL2 mRNA and protein 
levels, suggesting a potential inhibitory interaction.  However, these results could also be 
explained by a direct effect of estrogen agonists on BCL2 expression (80).  In contrast, 
our data support a direct interaction between miR-21 and the BCL2 3’UTR in beta cells, 
and provide direct evidence of miR-21’s effect on BCL2 mRNA levels as well as 
translation.  Moreover, we confirmed the link between miR-21 overexpression, 
reductions in BCL2, and increased apoptosis in human islets.  This novel report of miR-
21 inhibition of BCL2 may explain the unusual pro-apoptotic phenotype of miR-21 seen 
in the beta cell. Indeed, overexpression of BCL2 was able to reduce miR-21-mediated 
death in INS-1 cells.  
 There are several limitations to our study of miR-21’s effects on BCL2. BCL2 
overexpression has previously been shown to protect against cytokine-induced apoptosis 
in beta cell lines and islets ex vivo.  However, in vivo BCL2 overexpression delayed but 
was unable to fully prevent diabetes development in NOD mice (75, 81, 82).  While these 
data suggest that beta cell BCL2 overexpression may be partially protective, diabetes 
prevention in this model may require combinatorial approaches with a second 
intervention, such as immune modulation.  Similarly, as previous work has suggested that 
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loss of BCL2 may not be sufficient to induce apoptosis in isolation, key methodological 
differences in time frame and/or method of BCL2 reduction may explain our observed 
effects (83, 84).  
Lastly, BCL2 inhibition was recently shown to increase beta cell mitochondrial 
metabolism and glucose stimulated insulin secretion (83). Because miR-21 induced 
reductions in BCL2 might be expected to increase GSIS, our findings of decreased GSIS 
with miR-21 overexpression are likely not directly due to reduced BCL2 levels (83). Our 
results are most likely related to the progression of apoptosis and cell death present in a 
high percentage of cells, with subsequent degranulation and alterations in function.  
Alternatively, down-regulation of other suggested miR-21 target mRNAs, such as Pclo, 
which encodes a protein important for cyclic AMP potentiation of insulin secretion, may 
lead to effects on insulin secretion independent of miR-21’s effects on cell survival (49). 
Further investigation of other miR-21 target mRNAs is needed to fully understand the in-
vivo relevance of changes in beta cell miR-21 expression. 
Our findings also demonstrate that beta cell EV miR-21 cargo is increased in 
response to treatment with inflammatory cytokines. This increase was predominantly due 
to cytokine-induced effects on beta cell exosome miR-21.  We also report the novel 
observation that circulating EV miR-21 may be a biomarker of developing T1D, in that 
progressive elevations in serum EV miR-21 preceded hyperglycemia in NOD mice, and 
were present in pediatric subjects with new onset T1D. 
miRNA profiling in beta cells has demonstrated that the exosome contents differ 
from the cytoplasmic contents of cells of origin (85).  Our data point to an enrichment in 
the cytokine effect on miR-21 within beta cell exosomes, relative to intracellular miR-21. 
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Based on our data that miR-21 increases β cell apoptosis, it is tempting to speculate that 
exosome miR-21 may be involved in the proapoptotic effect of exosomal miRNA transfer 
from cytokine treated cells (86). Future studies will define the pathophysiologic 
significance of EV miR-21 transfer to recipient beta cells in the progression to T1D.  
We observed important differences between circulating total miR-21 and EV 
miR-21 levels.  Our findings of decreased serum miR-21 among T1D subjects are in 
contrast to several published reports of increased circulating miR-21 in patients with 
more established T1D (54, 55). However, reports describing total circulating miRNAs in 
new onset T1D or prediabetic patients, which would be more clinically consistent with 
our subject population, have not described differences in miR-21-5p (87-89).   
Although long-term incubation of islets with cytokines has been reported to 
increase exosome release, we did not observe a change in beta cell or islet EV quantity 
after 24 hours of cytokine treatment (40).  Lack of an increase in total EV count from 
islets or in serum of T1D subjects suggests that our observed increases in EV miR-21 are 
related to increases in miR-21 content per EV.  Our findings of parallel levels of miR-375 
in total serum and serum EVs suggest that differential miRNA concentrations in serum 
vs. serum EVs is not universal.  Differences among individuals with type 1 diabetes 
suggest that increases in these EV miRNAs could reflect different biological processes 
relating to type 1 diabetes pathophysiology, with differences depending on the 
mechanism of release of the miRNA being studied.  For example, miR-375 may be non-
selectively released by dying beta cells as both EV-independent circulating miRNA and 
in EVs, while miRNAs reflecting other components of the diabetic islet 
microenvironment could be selectively packaged into EVs.  These findings confirm the 
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importance of defining circulating EV miRNA content in addition to total circulating 
miRNA.   
Although we did observe variation among human subjects with T1D, there was a 
clear subset of type 1 diabetes subjects that displayed elevations in EV miR-21, with half 
of our diabetes samples above the range for control subjects.  This variation likely 
reflects the heterogeneous nature of T1D that has been observed in other clinical cohorts 
(90-92).   We did not observe a relationship with glycemic control; however, this may 
reflect the timing of sample collection (at clinical diagnoses, when all subjects had 
uncontrolled diabetes). 
Because miR-21 is a widely abundant miRNA, release from multiple tissue 
sources represents another likely source of variation in our study and is a significant 
limitation of work to define the biomarker potential of circulating miRNAs in general. 
However, our observations of consistent increases in EV miR-21 after cytokine exposure 
and before diabetes onset in the NOD mouse suggest that beta cell EV miR-21 is feasibly 
a major contributor to our observed signal in serum.  Emerging strategies to isolate islet 
or beta cell-derived EVs from the circulation are likely to increase the specificity of this 
assay and allow for earlier and more precise detection of developing T1D (93). 
Alternatively, identification of exosome subpopulations responsible for increased 
exosome miR-21, or a panel of circulating exosome miRNAs impacted during T1D 
development may provide a more robust signal (68, 69, 94).  
EV isolation methodology was an important consideration in our study.  As there 
is no consensus on the ideal method for EV enrichment from biological samples, 
recommendations based on the position statement from the International Society for 
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Extracellular Vesicles suggest the choice of methodology to be guided by “(a) the 
specific scientific question asked and (b) on the downstream applications used” (95, 96).  
Because ultracentrifugation is the most commonly utilized and accepted EV isolation 
method, we chose to perform ultracentrifugation to characterize EV subtypes from cell 
lines and islets (97, 98).  However, this method typically requires large sample volumes, 
limiting feasibility in clinical studies (99).  Based on this, we chose to use a precipitation-
based method to isolate total EVs for serum analyses in mice and children, which has also 
been demonstrated as an acceptable methodology for analysis of RNAs in circulating 
EVs (100-102). Our validation of EV isolation by NTA, immunoblot, and TEM suggests 
successful EV isolation using both methodologies. 
In conclusion, our results suggest a novel role for miR-21 in the beta cell through 
induction of apoptosis via BCL2 mRNA degradation and inhibition of BCL2 mRNA 
translation.  These findings provide important insight into the role of inflammation-
induced elevations in beta cell miR-21 during diabetes development. Our work also 
suggests that beta cells exposed to inflammatory stress release exosomes containing 
increased miR-21 cargo into the circulation, and that these EVs could serve as a 
biomarker of developing T1D.  Future work will utilize in vivo beta cell-specific models 
to study the effects of miR-21 over- and under-expression in order to define whether 
modulation of beta cell miR-21 levels may represent a potential target for strategies 
aimed at reducing beta cell death in diabetes.  Other future work will determine whether 
transfer of exosomal miR-21 to surrounding beta cells contributes to type 1 diabetes 
development, identify targets that allow for isolation of beta cell-specific EVs, and define 
other beta cell EV miRNAs affected during developing T1D.  Prospective evaluations of 
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human subjects are also indicated to determine whether glycemic control impacts 
circulating EV mir-21, and whether levels are predictive of differences in T1D clinical 
outcomes, such as honeymoon duration or loss of endogenous C-peptide secretion. 
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Lakhter A, Syed F, Maier B, Mirmira RG, Evans-Molina C, and Sims EK. “Elevated 
Levels of miR-21 in Circulating Extracellular Vesicles Predate Onset of Type 1 Diabetes 
Mellitus” Center for Diabetes and Metabolic Diseases Research Symposium. 2016.  
 
Pratt, R, Lakhter A, Syed F, Maier B, Mirmira RG, Evans-Molina C, and Sims EK. 
“Elevated Circulating Extracellular Vesicle miR-21 as a Noninvasive Marker of Insulitis 
Type 1 Diabetes Mellitus” Summer Research Program in Academic Medicine 
Symposium. 2016.  
 
Park, G, Liu Z, Mirmira RG, Mather K, Gupta S, and Sims EK.  Analysis of Beta Cell 
Death and Dysfunction in HIV Positive Individuals”  Summer Research Program in 
Academic Medicine Symposium. 2016.  
 
	Doucette K, Dumas M,  Lakhter A, Anderson-Baucum E, Sims EK. “Effects of miR-21 
on β cell insulin regulator, Spry2 in INS-1 Cells” CDMD Research Symposium. 2017. 
 
Neymann A, Nelson J, Tersey S, Mirmira R, Evans-Molina C, Sims EK. “Persistent 
Elevations in β- cell Death Among Subjects with Longstanding Type 1 Diabetes ” 
CDMD Research Symposium. 2017. 
 
Lakhter A, Syed F, Maier B, Mirmira RG, Evans-Molina C, and Sims EK. “Elevated 
Levels of miR-21 in Circulating Extracellular Vesicles Predate Onset of Type 1 Diabetes 
Mellitus” Center for Diabetes and Metabolic Diseases Research Symposium. 2017.  
*Selected for poster award   
  
Regional 
Sims EK, Hatanaka M, Tersey SA, Kono T, Moss DR, Stull ND, Mirmira RG, Evans-
Molina C.“Strain related differences in the response to diet-induced obesity and PPAR 
gamma agonists” Midwest Islet Club. 2012, Pittsburgh, PA 
 
Sims EK, Hatanaka M, Tersey SA, Kono T, Moss DR, Stull ND, Mirmira RG, Evans-
Molina C.“Strain related differences in the response to diet-induced obesity and PPAR 
gamma agonists” Midwest Islet Club. 2013, Ann Arbor, MI 
        
Sims EK, Restrepo I, Tong X, Kono T, Mirmira R, Evans-Molina C. “β-cell Derived 
miR-21 as an Intrinsic Protective Response and Biomarker in Type 1 Diabetes” Midwest 
Islet Club. 2014, Birmingham, AL 
 
Sims EK, Restrepo I, Tong X, Kono T Mirmira R, Evans-Molina C. “β-cell Derived 
miR-21 as a Proapoptotic Response and Biomarker in Type 1 Diabetes” Midwest Islet 
Club. 2015, Chicago, IL 
*Selected for poster award   
    
Sims EK, Lakhter A, Anderson-Baucum E, Restrepo I, Tong X, Kono T, Evans-Molina 
C. “miR-21 Increases Beta Cell Apoptosis Via Inhibition of the Antiapoptotic Protein B 
Cell Lymphoma 2, and Could Serve as a Biomarker Of Type 1 Diabetes Mellitus” Central 
Society for Clinical and Translational Research. 2016, Chicago, IL 
* Selected for CSCTR K Award Grant     
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“Elevated Circulating Extracellular Vesicle miR-21 as a Noninvasive Marker of Insulitis 
Type 1 Diabetes Mellitus” NIDDK Medical Student Summer Research Program in 
Diabetes and Obesity. 2016, Nashville, TN 
 
National 
Sims EK, Eugster EA, Nebesio TD “Detours on the road to diagnosis of  Graves 
Disease” 8th Joint Meeting of LWPES/ESPE. 2009, New York, NY 
     
	Sims EK, Garnett S, Guzman F, Sultan C, Eugster E, on behalf of the fulvestrant 
McCune-Albright study group. “Fulvestrant Treatment of Precocious Puberty in Girls 
with MAS”  Pediatric Endocrine Society Meeting. 2011,Denver, CO 
*Selected for Presidential Poster Presentation 
 
Sims EK, Hatanaka M, Tersey SA, Kono T, Moss DR, Stull ND, Mirmira RG, Evans-
Molina C.“Strain related differences in the response to diet-induced obesity and PPAR 
gamma agonists” Endocrine Society.  2012, Houston, TX. 
 
Sims EK, Hersch J, Haddad N, Imel EA. “Multilocus hypomethylation resulting in 
Beckwith Wiedemann Syndrome and Pseudohypoparathyroidism 1B in a 7 year-old girl” 
Pediatric Endocrine Society Meeting. 2013, Washington D.C. 
*Selected for Presidential Poster Presentation 
 
Sims EK, Hatanaka M, Tersey SA, Kono T, Moss DR, Stull ND, Mirmira RG, Evans-
Molina C.“Strain related differences in the response to diet-induced obesity and PPAR 
gamma agonists” Endocrine Society Meeting. 2013, San Francisco 
 
Sims EK, Ehsan Z, Howenstine M, Bozic M, Nebesio TD.  “Diabetes as the Initial 
Manifestation of Possible CFTR-Related Dysfunction in an Adolescent Male” Pediatric 
Endocrine Society Meeting. 2014, Vancouver 
 
Sims EK, Restrepo I, Tong X, Kono T, Mirmira R, and Evans-Molina C. “β-cell Derived 
miR-21 as an Intrinsic Protective Response and Biomarker in Type 1 Diabetes” American 
Society for Clinical Investigation. 2014, Chicago, IL 
 
Sims EK, Boulware D, Evans-Molina C, Greenbaum C, Rodriguez H, Krischer J, 
DiMeglio L and the T1D Trial NetStudy Group. “Who is Not Returning?  Recruitment of 
Subjects to the TrialNet Pathway to Prevention” American Diabetes Association. 2015, 
Boston, MA 
 
Sims EK, Restrepo I, Tong X, Kono T, Mirmira R, and Evans-Molina C. “β-cell Derived 
miR-21 as a Proapoptotic Response and Biomarker in Type 1 Diabetes”International 
Society for Extracellular Vesicles. 2015, Bethesda, MD 
   
Lakhter A, Syed F, Maier B, Mirmira RG, Evans-Molina C, and Sims EK. “Elevated 
Levels of miR-21 in Circulating Extracellular Vesicles Predate Onset of Type 1 Diabetes 
Mellitus” American Diabetes Association. 2016, New Orleans LA.  
 
Sims EK, DiMeglio L, Nelson J, Tersey S, Mirmira R, Evans-Molina C. “Circulating 
Unmethylated and Methylated Preproinsulin DNA in Longstanding Type 1 Diabetes” 
Human Islet Research Network Meeting. 2016, Washington D.C. 
 
Sims EK, Lakhter A, Anderson-Baucum E, Restrepo I, Tong X, Kono T, Evans-Molina 
C. “miR-21 Increases Beta Cell Apoptosis Via Inhibition of the Antiapoptotic Protein B 
Cell Lymphoma 2 (BCL2)” Pediatric Endocrine Society Meeting. 2016, Baltimore, MD. 
	 
Sims EK, Nyalwidhe J, Davis A, Haataja L, Ouyang F, Perkins S, DiMeglio LA, Blum J,  
Morris M, Mirmira RG, Nadler J, Mastracci T, Arvan P, Greenbaum C, and Evans-
Molina C.  Dysfunctional Proinsulin Processing in Longstanding Type 1 Diabetes” 
Endocrine Society and Levine Symposium. 2017, Orlando, FL. 
 
Hatanaka M, Anderson-Baucum E, Lakhter A, Kono T, Maier B, Tersey S, Tanizawa Y, 
Evans-Molina C, Mirmira RG, and Sims EK*.  “Chronic High Fat Feeding Restricts Islet 
mRNA Translation Initiation Independently of ER Stress Via DNA Damage and p53 
Activation” Endocrine Society and Levine Symposium. 2017, Orlando, FL. 
 
Lakhter, A, Pratt, R, Syed F, Maier B, Mirmira RG, Evans-Molina C, and Sims EK. 
“Elevations in EV miR-21 as a Biomarker of Developing T1D” Levine Symposium 2017; 
Orlando, FL. 
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TEACHING ACTIVITIES: 
  
Type 1 Diabetes- Pediatric Resident Lecture    2013- 2017 
 
Growth- Medical Student Clinical Rotation Lecture Series   2014-2015  
 
Hypothyroidism Pediatric Endocrine Fellows Lecture   2014 
 
Hormone Stimulation Testing- Pediatric Endocrine Fellows Lecture 2014-2017 
 
Putting Together a Specific Aims Page- Morris Green Research  2015-2016 
Scholars Lecture 
 
Pituitary Dysfunction-  Pediatric Endocrine Fellow Lecture   2016 
 
Type 1 Diabetes- Medical Student Clinical Rotation Lecture Series  2016-2017 
 
Basic Science Techniques- Pediatric Endocrine Fellow Lecture  2017-2018  
 
PROFESSIONAL SERVICE:   
Institutional:  
Wells Intern Summer Research Day  oral presentation judge 2015 
 
Center for Diabetes and Metabolic  poster judge   2016 
Diseases Annual Symposium 
 
Committee for Pediatric Endocrine Grand Rounds Cochair   2016-2019 
	 
Indiana University Clinical and   grant reviewer   2017 
Translational Sciences Institute- Pilot 
Funding for Research Use of Core  
Facilities 
 
Regional: 
American Diabetes Association Volunteer at diabetes camp 2012-2016      
     
Central Society for Clinical and   abstract reviewer  2013-2017 
Translational Research          
 
American Diabetes Association  speaker at research day 2014, 2015  
      and ask the expert events 
 
Midwest Islet Club    Session Moderator,   2016, 2017 
abstract reviewer  
 
National: 
 
National Association for Rare Disorders editor for patient report on 2014-2016 
      on MAS 
 
NIH NIDDK Special Emphasis Panel ad hoc reviewer  2015 
ZDK1-GRB-S(M1) 
 
Michigan Diabetes Research Center  ad hoc reviewer   2017 
Pilot and Feasibility Study Grant 
Program 
 
Pediatric Endocrine Society   abstract reviewer   2017 
 
Endocrine Society    Peds Endocrine associate editor 2017 
      Medscape/Endocrine Society 
      Consults 
 
Invited Scientific Journal Peer Review 
Journal of Diabetes and its Complications    
American Journal of Physiology: Endocrinology and Metabolism 
Molecular Endocrinology        
Journal of Endocrinology and Diabetes Mellitus 
Journal of Pediatric Surgery      
Diabetes Technology and Therapeutics     
Orphanet Journal of Rare Diseases     
Endocrine Practice       
Pediatrics        
	Scientific Reports       
Endocrinology     
Acta Diabetologica       
Journal of Clinical Investigation     
Diabetes 
Diabetes Care      
Diabetologia 
 
